Free Trial

HUTCHMED (NASDAQ:HCM) Shares Gap Down - What's Next?

HUTCHMED logo with Medical background

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $16.79, but opened at $16.01. HUTCHMED shares last traded at $15.95, with a volume of 1,309 shares.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on HCM shares. Wall Street Zen lowered shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research note on Saturday, June 14th. HSBC downgraded HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th.

Check Out Our Latest Stock Report on HCM

HUTCHMED Stock Performance

The business has a 50-day moving average price of $14.64 and a two-hundred day moving average price of $14.71. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.70 and a current ratio of 2.83.

Institutional Investors Weigh In On HUTCHMED

A number of large investors have recently modified their holdings of the company. Jane Street Group LLC increased its holdings in shares of HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company's stock valued at $3,343,000 after acquiring an additional 124,771 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company's stock valued at $1,413,000 after acquiring an additional 7,342 shares during the last quarter. Vident Advisory LLC raised its holdings in shares of HUTCHMED by 78.3% in the 1st quarter. Vident Advisory LLC now owns 19,728 shares of the company's stock worth $297,000 after purchasing an additional 8,664 shares during the period. XY Capital Ltd lifted its stake in shares of HUTCHMED by 142.4% during the first quarter. XY Capital Ltd now owns 113,136 shares of the company's stock worth $1,702,000 after purchasing an additional 66,460 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its holdings in HUTCHMED by 31.4% in the 1st quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company's stock worth $367,000 after buying an additional 5,829 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

About HUTCHMED

(Get Free Report)

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

See Also

Should You Invest $1,000 in HUTCHMED Right Now?

Before you consider HUTCHMED, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.

While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines